Argent Biopharma Limited has released a press release.
Refinancing and Extension to Convertible Security Agreements
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Argent Biopharma
- Results of CimetrA bioanalytics pre-clinal trial
- Internal Costs Review Completed and Board Change
- $800,000 of funding received through Mercer Facility
- Completion of CimetrA Efficacy Pre-clinical Trial
- US$1,000,000 ArtemiC order delivered to US partner, AMC
Later from Argent Biopharma
- Provision of US$600,000 Funding and change of CFO
- Completion of CimetrA Mechanism of Action study
- ArtemiC Listed as OTC Drug in USA, AMC Places US$2m Order
- MGC Receive Permission for Psilocybin Research & Development
- Funding Commitments Received for GBP 1.8m
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma